Skip to main content
Clinical Trials/IRCT20170702034844N7
IRCT20170702034844N7RecruitingPhase 3

Comparison of buprenorphine and methadone maintenance treatments in prison: a randomized controlled trial

Faran Shimi Pharmaceutical Company0 sites100 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
Phase 3
Status
Recruiting
Sponsor
Enrollment
100

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 years to 50 years (—)
Sex
Male

Inclusion Criteria

  • Diagnosis of moderate to severe opioid use disorder based on DSM-5
  • Continuous consumption of illegal opioids in the past month prior to incarceration
  • Age 18 to 50 years
  • Informed written consent to enter the study
  • Conviction period more than 6 months

Exclusion Criteria

  • Concurrent diagnosis of other substance use disorders (except tobacco)
  • Uncontrolled severe psychiatric disorders including serious suicidality or psychosis based on a study physician's diagnosis
  • Severe and uncontrolled physical conditions including unstable angina, liver failure and a history of myocardial infarction during last month based on physician' s diagnosis and laboratory evaluations
  • Inability to understand the study protocol or respond to study assessments
  • More than three times raise of liver enzymes

Investigators

Sponsor
Faran Shimi Pharmaceutical Company

Similar Trials

Comparison of opioid maintenance... | Clinical Trial